June 1, 2016
Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering
Clearside Biomedical, Inc.(NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, announced its initial public offering of 7,200,000 shares of its common stock at a public offering price of $7.00 per share. In addition, Clearside has granted the underwriters a 30-day option to purchase up to an additional 1,080,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The shares are trading on the NASDAQ Global Market under the ticker symbol “CLSD.” All of the common stock is being offered by Clearside.
